SAN JUAN, Puerto Rico, July 28, 2017 /PRNewswire/ -- Abarca Health, a pharmacy benefit management (PBM) and technology
"We are excited to partner with Biogen in implementing this innovative, data-driven, and outcomes-based pricing program for MS drug therapies. We believe this program is a significant milestone in our efforts to collaborate with pharmaceutical manufacturers to find a better way to guide patients and payers down the path to value, especially in high impact disease categories," stated Javier Gonzalez, Chief Operating Officer of Abarca Health.
This contract builds on Abarca Health's ongoing work with Biogen to find better ways to collaborate in the treatment of patients afflicted with complex, high-cost conditions.
"We believe that contracting approaches like this will help expand access for patients. We are excited to work with an innovative partner like Abarca Health and lead the way for MS care," said Jean-Paul Kress, Executive Vice President and President, International and Head of Global Therapeutic Operations of Biogen.
Outcomes-based contracting is an important part of the future of healthcare. By partnering with manufacturers such as Biogen, Abarca Health is ensuring greater accountability around the investments made by payers and patients in high cost treatments, which leads to better access and better outcomes for patients.
About ABARCA HEALTH
As a pharmacy benefit management and technology company, Abarca Health serves more than 2 million people across the nation helping its clients manage over $1 billion per year in pharmaceutical spending. The company leverages its people, culture and technology to develop deep partnerships with health plans, government programs, self-insuring employer/union groups, and other payers - partnerships that are both authentic and flexible. By building trust with and delivering consistently for its customers, Abarca is able to better work together to create a healthcare experience that cares for us like family, guides us on the path to value, and inspires us to live better every day. For more information, please visit www.abarcahealth.com.
View original content:http://www.prnewswire.com/news-releases/abarca-health-announces-innovative-value-based-contract-with-biogen-for-multiple-sclerosis-therapies-300495968.html
SOURCE Abarca Health
Subscribe to our Free Newsletters!
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...View All